{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T05:01:17Z","timestamp":1790312477224,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Natural Science Foundation of China","award":["82573590"],"award-info":[{"award-number":["82573590"]}]},{"name":"National Major Science and Technology Projects of China","award":["2025ZD0552502"],"award-info":[{"award-number":["2025ZD0552502"]}]},{"name":"CSCO Clinical Oncology Research Foundation","award":["Y-Gilead2024-PT-0080"],"award-info":[{"award-number":["Y-Gilead2024-PT-0080"]}]},{"name":"Sun Yat-Sen Memorial Hospital Clinical Research 5010 Program","award":["SYS-5010-202508"],"award-info":[{"award-number":["SYS-5010-202508"]}]},{"name":"Sun Yat-Sen Memorial Hospital Medical Scientist Program","award":["1320900074"],"award-info":[{"award-number":["1320900074"]}]},{"name":"Guangdong Provincial Key Laboratory of Cancer Pathogenesis and Precision Diagnosis and Treatment","award":["2024B1212030002"],"award-info":[{"award-number":["2024B1212030002"]}]},{"name":"DCMST.NHC Clinical Research Project","award":["WKZX2023CX050002"],"award-info":[{"award-number":["WKZX2023CX050002"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s10549-026-08066-5","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T08:01:59Z","timestamp":1788163319000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy, safety, and biomarker analysis of neoadjuvant camrelizumab plus apatinib as a chemotherapy-free strategy for early-stage triple-negative breast cancer: a phase II study"],"prefix":"10.1007","volume":"219","author":[{"given":"Zhenluan","family":"Tian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hengyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herui","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heran","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7859-3764","authenticated-orcid":false,"given":"Jieqiong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"issue":"3","key":"8066_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74(3):229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"8066_CR2","doi-asserted-by":"publisher","first-page":"452","DOI":"10.6004\/jnccn.2020.0016","volume":"18","author":"WJ Gradishar","year":"2020","unstructured":"Gradishar WJ, Anderson BO, Abraham J, Aft R, Agnese D, Allison KH et al (2020) Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 18(4):452\u2013478. https:\/\/doi.org\/10.6004\/jnccn.2020.0016","journal-title":"J Natl Compr Canc Netw"},{"key":"8066_CR3","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Breast Cancer Version 4.2025"},{"issue":"9938","key":"8066_CR4","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/s0140-6736(13)62422-8","volume":"384","author":"P Cortazar","year":"2014","unstructured":"Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N et al (2014) Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet (London England) 384(9938):164\u2013172. https:\/\/doi.org\/10.1016\/s0140-6736(13)62422-8","journal-title":"Lancet (London England)"},{"issue":"9","key":"8066_CR5","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid P, Cortes J, Pusztai L, McArthur H, K\u00fcmmel S, Bergh J et al (2020) Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med 382(9):810\u2013821. https:\/\/doi.org\/10.1056\/NEJMoa1910549","journal-title":"N Engl J Med"},{"issue":"21","key":"8066_CR6","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1056\/NEJMoa2409932","volume":"391","author":"P Schmid","year":"2024","unstructured":"Schmid P, Cortes J, Dent R, McArthur H, Pusztai L, K\u00fcmmel S et al (2024) Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer. N Engl J Med 391(21):1981\u20131991. https:\/\/doi.org\/10.1056\/NEJMoa2409932","journal-title":"N Engl J Med"},{"issue":"8","key":"8066_CR7","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1001\/jama.2024.23560","volume":"333","author":"L Chen","year":"2025","unstructured":"Chen L, Li H, Zhang H, Yang H, Qian J, Li Z et al (2025) Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer: The CamRelief Randomized Clinical Trial. JAMA 333(8):673\u2013681. https:\/\/doi.org\/10.1001\/jama.2024.23560","journal-title":"JAMA"},{"issue":"10257","key":"8066_CR8","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/s0140-6736(20)31953-x","volume":"396","author":"EA Mittendorf","year":"2020","unstructured":"Mittendorf EA, Zhang H, Barrios CH, Saji S, Jung KH, Hegg R et al (2020) Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. Lancet 396(10257):1090\u20131100. https:\/\/doi.org\/10.1016\/s0140-6736(20)31953-x","journal-title":"Lancet"},{"issue":"7","key":"8066_CR9","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1038\/s41591-025-03725-4","volume":"31","author":"EA Mittendorf","year":"2025","unstructured":"Mittendorf EA, Assaf ZJ, Harbeck N, Zhang H, Saji S, Jung KH et al (2025) Peri-operative atezolizumab in early-stage triple-negative breast cancer: final results and ctDNA analyses from the randomized phase 3 IMpassion031 trial. Nat Med 31(7):2397\u20132404. https:\/\/doi.org\/10.1038\/s41591-025-03725-4","journal-title":"Nat Med"},{"issue":"15","key":"8066_CR10","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1200\/jco.22.00503","volume":"40","author":"LA Korde","year":"2022","unstructured":"Korde LA, Somerfield MR, Hershman DL (2022) Use of Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer: ASCO Guideline Rapid Recommendation Update. J Clin Oncol 40(15):1696\u20131698. https:\/\/doi.org\/10.1200\/jco.22.00503","journal-title":"J Clin Oncol"},{"issue":"7","key":"8066_CR11","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1158\/1078-0432.Ccr-19-2179","volume":"26","author":"Q Li","year":"2020","unstructured":"Li Q, Wang Y, Jia W, Deng H, Li G, Deng W et al (2020) Low-Dose Anti-Angiogenic Therapy Sensitizes Breast Cancer to PD-1 Blockade. Clin Cancer Res 26(7):1712\u20131724. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-19-2179","journal-title":"Clin Cancer Res"},{"key":"8066_CR12","doi-asserted-by":"publisher","unstructured":"Liu J, Liu Q, Li Y, Li Q, Su F, Yao H et al (2020) Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial. J Immunother Cancer 8(1). https:\/\/doi.org\/10.1136\/jitc-2020-000696","DOI":"10.1136\/jitc-2020-000696"},{"issue":"6","key":"8066_CR13","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.jtho.2023.02.019","volume":"18","author":"J Zhao","year":"2023","unstructured":"Zhao J, Zhao L, Guo W, Wang S, Tao X, Li L et al (2023) Efficacy, Safety, and Biomarker Analysis of Neoadjuvant Camrelizumab and Apatinib in Patients With Resectable NSCLC: A Phase 2 Clinical Trial. J Thorac Oncol 18(6):780\u2013791. https:\/\/doi.org\/10.1016\/j.jtho.2023.02.019","journal-title":"J Thorac Oncol"},{"key":"8066_CR14","doi-asserted-by":"publisher","first-page":"S1206","DOI":"10.1016\/j.annonc.2024.08.2249","volume":"35","author":"I Nederlof","year":"2024","unstructured":"Nederlof I, Rolfes AL, Gielen RCAM, Awada G, Dongen MV, Horlings HM et al (2024) LBA11 Neoadjuvant nivolumab\/relatlimab or nivolumab\/ipilimumab in triple negative breast cancer with high tumor-infiltrating lymphocytes (TILs). Ann Oncol 35:S1206. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.2249","journal-title":"Ann Oncol"},{"issue":"2","key":"8066_CR15","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/annonc\/mdu450","volume":"26","author":"R Salgado","year":"2015","unstructured":"Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G et al (2015) The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol 26(2):259\u2013271. https:\/\/doi.org\/10.1093\/annonc\/mdu450","journal-title":"Ann Oncol"},{"issue":"27","key":"8066_CR16","doi-asserted-by":"publisher","first-page":"4433","DOI":"10.1200\/jco.23.00435","volume":"41","author":"JK Litton","year":"2023","unstructured":"Litton JK, Regan MM, Pusztai L, Rugo HS, Tolaney SM, Garrett-Mayer E et al (2023) Standardized Definitions for Efficacy End Points in Neoadjuvant Breast Cancer Clinical Trials: NeoSTEEP. J Clin oncology: official J Am Soc Clin Oncol 41(27):4433\u20134442. https:\/\/doi.org\/10.1200\/jco.23.00435","journal-title":"J Clin oncology: official J Am Soc Clin Oncol"},{"key":"8066_CR17","doi-asserted-by":"publisher","unstructured":"Tolaney SM, Garrett-Mayer E, White J, Blinder VS, Foster JC, Amiri-Kordestani L et al (2021) Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 39(24):2720\u20132731. https:\/\/doi.org\/10.1200\/jco.20.03613","DOI":"10.1200\/jco.20.03613"},{"issue":"4","key":"8066_CR18","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1002\/ijc.33830","volume":"150","author":"L Zhang","year":"2022","unstructured":"Zhang L, Wu ZY, Li J, Lin Y, Liu Z, Cao Y et al (2022) Neoadjuvant docetaxel plus carboplatin vs epirubicin plus cyclophosphamide followed by docetaxel in triple-negative, early-stage breast cancer (NeoCART): Results from a multicenter, randomized controlled, open-label phase II trial. Int J Cancer 150(4):654\u2013662. https:\/\/doi.org\/10.1002\/ijc.33830","journal-title":"Int J Cancer"},{"issue":"7","key":"8066_CR19","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/s1470-2045(14)70160-3","volume":"15","author":"G von Minckwitz","year":"2014","unstructured":"von Minckwitz G, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M et al (2014) Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol 15(7):747\u2013756. https:\/\/doi.org\/10.1016\/s1470-2045(14)70160-3","journal-title":"Lancet Oncol"},{"issue":"3","key":"8066_CR20","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s10549-021-06128-4","volume":"186","author":"J Liu","year":"2021","unstructured":"Liu J, Li Y, Li Q, Liang D, Wang Q, Liu Q (2021) Biomarkers of response to camrelizumab combined with apatinib: an analysis from a phase II trial in advanced triple-negative breast cancer patients. Breast Cancer Res Treat 186(3):687\u2013697. https:\/\/doi.org\/10.1007\/s10549-021-06128-4","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"8066_CR21","doi-asserted-by":"publisher","first-page":"104122","DOI":"10.1016\/j.esmoop.2024.104122","volume":"10","author":"K Sugiyama","year":"2025","unstructured":"Sugiyama K, Gordon A, Popat S, Okines A, Larkin J, Chau I (2025) Is pathological response an adequate surrogate marker for survival in neoadjuvant therapy with immune checkpoint inhibitors? ESMO Open 10(2):104122. https:\/\/doi.org\/10.1016\/j.esmoop.2024.104122","journal-title":"ESMO Open"},{"issue":"12","key":"8066_CR22","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1016\/s1470-2045(25)00546-7","volume":"26","author":"F Conforti","year":"2025","unstructured":"Conforti F, Holtschmidt J, Nekljudova V, Sala I, Pagan E, Solbach C et al (2025) Distant disease-free survival as a surrogate endpoint for overall survival in randomised trials of neoadjuvant therapy for early breast cancer: a pooled analysis of GBG and AGO-B Study Group trials. Lancet Oncol 26(12):1584\u20131597. https:\/\/doi.org\/10.1016\/s1470-2045(25)00546-7","journal-title":"Lancet Oncol"},{"key":"8066_CR23","doi-asserted-by":"publisher","unstructured":"Sonia N, Mondal S, Limaye AM (2025) Expression of MMP-11, an estrogen-suppressed gene in MCF-7 cells, is elevated upon acquisition of tamoxifen resistance. bioRxiv.2025.02.13.638037. https:\/\/doi.org\/10.1101\/2025.02.13.638037","DOI":"10.1101\/2025.02.13.638037"},{"issue":"12","key":"8066_CR24","doi-asserted-by":"publisher","first-page":"13499","DOI":"10.3390\/cimb46120806","volume":"46","author":"Y-C Chen","year":"2024","unstructured":"Chen Y-C, Chen C-C, Chen R-F, Chen H-H, Chen P-M (2024) SPP1 mRNA Expression Is Associated with M2 Macrophage Infiltration and Poor Prognosis in Triple-Negative Breast Cancer. Curr Issues Mol Biol 46(12):13499\u201313513","journal-title":"Curr Issues Mol Biol"},{"issue":"12","key":"8066_CR25","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1016\/j.immuni.2023.11.002","volume":"56","author":"T Taifour","year":"2023","unstructured":"Taifour T, Attalla SS, Zuo D, Gu Y, Sanguin-Gendreau V, Proud H et al (2023) The tumor-derived cytokine Chi3l1 induces neutrophil extracellular traps that promote T cell exclusion in triple-negative breast cancer. Immunity 56(12):2755\u201372e8. https:\/\/doi.org\/10.1016\/j.immuni.2023.11.002","journal-title":"Immunity"},{"issue":"1","key":"8066_CR26","doi-asserted-by":"publisher","first-page":"10107","DOI":"10.1038\/s41467-024-54435-3","volume":"15","author":"K G\u0142owacka","year":"2024","unstructured":"G\u0142owacka K, Ibanez S, Renoult O, Vermonden P, Giolito MV, \u00d6zkan K et al (2024) Acid-exposed and hypoxic cancer cells do not overlap but are interdependent for unsaturated fatty acid resources. Nat Commun 15(1):10107. https:\/\/doi.org\/10.1038\/s41467-024-54435-3","journal-title":"Nat Commun"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-08066-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-026-08066-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-08066-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:54:26Z","timestamp":1790312066000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-026-08066-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["8066"],"URL":"https:\/\/doi.org\/10.1007\/s10549-026-08066-5","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]},"assertion":[{"value":"21 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This trial protocol was performed in accordance with the Declaration of Helsinki guidelines and approved by the ethics committee of each participating institution. The study is registered at ClinicalTrials.gov under the identifier NCT05556200 (registration date: September 27, 2022).","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants provided written informed consent for the publication of anonymized data.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants provided written informed consent prior to study enrollment.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"3"}}